Adagene, Sanofi collaborate on masked immuno-oncology antibody candidates
Adagene will conduct early-stage research to develop masked versions of Sanofi’s antibody candidates using its SAFEbody technology
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Mar 22
Adagene will conduct early-stage research to develop masked versions of Sanofi’s antibody candidates using its SAFEbody technology
02 Mar 22
The acquisition will expand AbbVie's neuroscience portfolio with Syndesi’s synaptic vesicle protein 2A (SV2A) modulators, including its lead…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Mar 22
Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…
01 Mar 22
In the CARTITUDE-1 study, 98% of patients with RRMM responded to a one-time treatment with Carvykti, while 78%…
28 Feb 22
A look at the number of ethical and practical benefits that the direct-to-patient model of clinical trial offers…
28 Feb 22
Through the acquisition, BBL will obtain rights to Viatris’ biosimilars business assets, which is estimated to generate $1bn…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Feb 22
In the CLEAR/KEYNOTE-581 trial, Keytruda plus Lenvima significantly reduced the risk of disease progression or death by 61%,…
25 Feb 22
The FDA approval is supported by results from the Phase 3 EMPEROR-Preserved trial in which Jardiance showed a…
25 Feb 22
Covifenz leverages CoVLP technology, comprises recombinant spike (S) glycoprotein, and is co-administered with GSK’s pandemic adjuvant
24 Feb 22
Sanofi and GSK’s vaccine is said to have induced superior immune responses and a favourable safety profile, both…